Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl

Trial Profile

Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Avelumab (Primary) ; Azacitidine; Bendamustine; Gemcitabine; Oxaliplatin; Rituximab; Utomilumab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms JAVELIN DLBCL
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 May 2021 to 29 May 2021.
    • 24 Jul 2017 Planned primary completion date changed from 1 Feb 2021 to 2 Feb 2021.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top